Fortress Total Liab vs Net Invested Capital Analysis

FBIO Stock

USD 1.84 0.16 9.52%

Fortress Biotech financial indicator trend analysis is much more than just examining Fortress Biotech latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fortress Biotech is a good investment. Please check the relationship between Fortress Biotech Total Liab and its Net Invested Capital accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fortress Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Fortress Stock, please use our How to Invest in Fortress Biotech guide.

Total Liab vs Net Invested Capital

Total Liab vs Net Invested Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fortress Biotech Total Liab account and Net Invested Capital. At this time, the significance of the direction appears to have very week relationship.

The correlation between Fortress Biotech's Total Liab and Net Invested Capital is 0.23. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Net Invested Capital in the same time period over historical financial statements of Fortress Biotech, assuming nothing else is changed. The correlation between historical values of Fortress Biotech's Total Liab and Net Invested Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Fortress Biotech are associated (or correlated) with its Net Invested Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Invested Capital has no effect on the direction of Total Liab i.e., Fortress Biotech's Total Liab and Net Invested Capital go up and down completely randomly.

Correlation Coefficient

0.23

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Net Invested Capital

The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.

Most indicators from Fortress Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fortress Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fortress Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Fortress Stock, please use our How to Invest in Fortress Biotech guide.At this time, Fortress Biotech's Selling General Administrative is very stable compared to the past year. As of the 26th of November 2024, Issuance Of Capital Stock is likely to grow to about 92.5 M, though Discontinued Operations is likely to grow to (9.5 M).

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	6.8M	9.4M	8.1M	8.5M
Research Development	128.9M	134.9M	106.1M	59.7M

Depreciation And Amortization Research Development

Fortress Biotech fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Other Current Liab	Total Current Liabilities	Accounts Payable	Cash	Other Assets	Long Term Debt	Other Current Assets	Total Liab	Common Stock	Property Plant Equipment	Total Stockholder Equity	Preferred Stock Total Equity	Short Long Term Debt Total	Net Debt	Retained Earnings	Cash And Short Term Investments	Common Stock Total Equity	Retained Earnings Total Equity	Short Term Investments	Non Current Liabilities Total	Other Stockholder Equity	Total Current Assets	Intangible Assets	Other Liab
Common Stock Shares Outstanding		0.28	0.6	0.47	0.38	0.25	-0.32	0.33	0.33	0.45	-0.21	0.61	-0.06	-0.14	0.39	-0.02	-0.54	0.2	-0.14	-0.4	0.17	0.39	0.53	0.27	0.47	-0.08
Total Assets	0.28		0.68	0.8	0.75	0.95	0.2	0.75	0.76	0.83	0.25	0.71	0.59	-0.4	0.78	-0.64	-0.73	0.96	0.25	-0.87	0.61	0.79	0.85	0.98	0.67	0.26
Other Current Liab	0.6	0.68		0.79	0.62	0.65	-0.29	0.55	0.6	0.73	-0.31	0.92	0.27	-0.21	0.61	-0.31	-0.83	0.64	-0.21	-0.76	0.31	0.62	0.8	0.69	0.86	0.05
Total Current Liabilities	0.47	0.8	0.79		0.95	0.66	0.14	0.81	0.79	0.95	0.23	0.77	0.14	-0.24	0.82	-0.26	-0.83	0.67	0.26	-0.85	0.58	0.82	0.88	0.76	0.83	0.43
Accounts Payable	0.38	0.75	0.62	0.95		0.59	0.28	0.86	0.72	0.94	0.46	0.67	0.01	-0.28	0.86	-0.14	-0.78	0.61	0.49	-0.83	0.63	0.85	0.82	0.7	0.73	0.52
Cash	0.25	0.95	0.65	0.66	0.59		-0.01	0.57	0.56	0.68	0.07	0.65	0.72	-0.37	0.63	-0.8	-0.62	0.99	0.06	-0.76	0.39	0.64	0.75	0.98	0.52	0.04
Other Assets	-0.32	0.2	-0.29	0.14	0.28	-0.01		0.25	0.42	0.16	0.66	-0.18	-0.01	-0.2	0.17	0.11	0.01	0.09	0.63	-0.09	0.67	0.16	0.02	0.11	0.11	0.57
Long Term Debt	0.33	0.75	0.55	0.81	0.86	0.57	0.25		0.73	0.94	0.53	0.68	0.01	-0.36	0.99	-0.02	-0.83	0.58	0.57	-0.89	0.64	0.99	0.86	0.66	0.69	0.37
Other Current Assets	0.33	0.76	0.6	0.79	0.72	0.56	0.42	0.73		0.79	0.32	0.68	0.2	-0.32	0.72	-0.19	-0.71	0.6	0.36	-0.76	0.73	0.72	0.77	0.67	0.81	0.63
Total Liab	0.45	0.83	0.73	0.95	0.94	0.68	0.16	0.94	0.79		0.36	0.79	0.12	-0.31	0.95	-0.2	-0.88	0.69	0.39	-0.93	0.63	0.95	0.93	0.77	0.8	0.38
Common Stock	-0.21	0.25	-0.31	0.23	0.46	0.07	0.66	0.53	0.32	0.36		-0.05	-0.23	-0.18	0.48	0.2	-0.16	0.13	0.97	-0.3	0.55	0.44	0.18	0.17	-0.04	0.61
Property Plant Equipment	0.61	0.71	0.92	0.77	0.67	0.65	-0.18	0.68	0.68	0.79	-0.05		0.17	-0.25	0.75	-0.2	-0.96	0.66	0.09	-0.89	0.46	0.75	0.89	0.72	0.83	0.17
Total Stockholder Equity	-0.06	0.59	0.27	0.14	0.01	0.72	-0.01	0.01	0.2	0.12	-0.23	0.17		-0.27	0.07	-0.89	-0.08	0.71	-0.31	-0.23	0.2	0.08	0.29	0.64	0.08	-0.3
Preferred Stock Total Equity	-0.14	-0.4	-0.21	-0.24	-0.28	-0.37	-0.2	-0.36	-0.32	-0.31	-0.18	-0.25	-0.27		-0.34	0.13	0.34	-0.33	-0.19	0.42	-0.29	-0.34	-0.37	-0.34	-0.27	-0.16
Short Long Term Debt Total	0.39	0.78	0.61	0.82	0.86	0.63	0.17	0.99	0.72	0.95	0.48	0.75	0.07	-0.34		-0.09	-0.86	0.64	0.53	-0.92	0.63	1.0	0.89	0.71	0.7	0.32
Net Debt	-0.02	-0.64	-0.31	-0.26	-0.14	-0.8	0.11	-0.02	-0.19	-0.2	0.2	-0.2	-0.89	0.13	-0.09		0.09	-0.78	0.3	0.26	-0.05	-0.11	-0.3	-0.71	-0.08	0.2
Retained Earnings	-0.54	-0.73	-0.83	-0.83	-0.78	-0.62	0.01	-0.83	-0.71	-0.88	-0.16	-0.96	-0.08	0.34	-0.86	0.09		-0.63	-0.29	0.96	-0.55	-0.86	-0.94	-0.71	-0.83	-0.28
Cash And Short Term Investments	0.2	0.96	0.64	0.67	0.61	0.99	0.09	0.58	0.6	0.69	0.13	0.66	0.71	-0.33	0.64	-0.78	-0.63		0.13	-0.77	0.49	0.64	0.74	0.99	0.54	0.11
Common Stock Total Equity	-0.14	0.25	-0.21	0.26	0.49	0.06	0.63	0.57	0.36	0.39	0.97	0.09	-0.31	-0.19	0.53	0.3	-0.29	0.13		-0.39	0.58	0.49	0.24	0.18	0.06	0.65
Retained Earnings Total Equity	-0.4	-0.87	-0.76	-0.85	-0.83	-0.76	-0.09	-0.89	-0.76	-0.93	-0.3	-0.89	-0.23	0.42	-0.92	0.26	0.96	-0.77	-0.39		-0.61	-0.92	-0.96	-0.83	-0.77	-0.33
Short Term Investments	0.17	0.61	0.31	0.58	0.63	0.39	0.67	0.64	0.73	0.63	0.55	0.46	0.2	-0.29	0.63	-0.05	-0.55	0.49	0.58	-0.61		0.61	0.6	0.55	0.49	0.45
Non Current Liabilities Total	0.39	0.79	0.62	0.82	0.85	0.64	0.16	0.99	0.72	0.95	0.44	0.75	0.08	-0.34	1.0	-0.11	-0.86	0.64	0.49	-0.92	0.61		0.9	0.72	0.71	0.3
Other Stockholder Equity	0.53	0.85	0.8	0.88	0.82	0.75	0.02	0.86	0.77	0.93	0.18	0.89	0.29	-0.37	0.89	-0.3	-0.94	0.74	0.24	-0.96	0.6	0.9		0.81	0.77	0.22
Total Current Assets	0.27	0.98	0.69	0.76	0.7	0.98	0.11	0.66	0.67	0.77	0.17	0.72	0.64	-0.34	0.71	-0.71	-0.71	0.99	0.18	-0.83	0.55	0.72	0.81		0.62	0.18
Intangible Assets	0.47	0.67	0.86	0.83	0.73	0.52	0.11	0.69	0.81	0.8	-0.04	0.83	0.08	-0.27	0.7	-0.08	-0.83	0.54	0.06	-0.77	0.49	0.71	0.77	0.62		0.38
Other Liab	-0.08	0.26	0.05	0.43	0.52	0.04	0.57	0.37	0.63	0.38	0.61	0.17	-0.3	-0.16	0.32	0.2	-0.28	0.11	0.65	-0.33	0.45	0.3	0.22	0.18	0.38

Click cells to compare fundamentals

Fortress Biotech Account Relationship Matchups

Fortress Biotech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	3.6M	4.8M	5.4M	5.9M	8.1M	4.5M
Total Assets	226.4M	328.8M	396.5M	294.3M	167.5M	173.1M
Other Current Liab	27K	33.8M	43.2M	56.4M	39.8M	41.8M
Total Current Liabilities	45.6M	48.0M	101.0M	127.7M	84.9M	46.5M
Accounts Payable	35.5M	11.4M	47.4M	57.2M	34.8M	21.0M
Cash	136.9M	233.4M	305.7M	178.3M	80.9M	112.2M
Other Assets	16.4M	17.7M	2.7M	3.4M	3.9M	3.7M
Long Term Debt	82.4M	59.0M	46.6M	93.1M	60.9M	42.4M
Other Current Assets	4.1M	12.0M	7.1M	9.7M	10.5M	5.5M
Total Liab	153.9M	131.8M	170.6M	244.3M	165.9M	96.1M
Common Stock	574K	95K	101K	110K	15K	14.3K
Property Plant Equipment	12.0M	12.4M	32.4M	34.1M	39.2M	41.1M
Total Stockholder Equity	26.2M	100.3M	108.7M	41.7M	22.5M	21.4M
Short Long Term Debt Total	115.1M	89.1M	75.0M	127.3M	88.6M	62.1M
Noncontrolling Interest In Consolidated Entity	17.9M	46.3M	96.7M	117.2M	134.8M	141.5M
Net Debt	(21.7M)	(144.3M)	(230.8M)	(50.9M)	7.7M	8.0M
Retained Earnings	(436.2M)	(482.8M)	(547.5M)	(634.2M)	(694.9M)	(660.1M)
Cash And Short Term Investments	136.9M	233.4M	305.7M	178.3M	80.9M	134.9M
Common Stock Total Equity	717K	574K	95K	101K	116.2K	226.3K
Retained Earnings Total Equity	(396.3M)	(436.2M)	(482.8M)	(547.5M)	(492.7M)	(468.1M)
Short Term Investments	39.0M	17.6M	15M	17.6M	20.2M	12.4M
Liabilities And Stockholders Equity	226.4M	328.8M	396.5M	294.3M	167.5M	198.4M
Non Current Liabilities Total	108.3M	83.9M	69.6M	116.6M	81.0M	57.1M
Inventory	857K	1.4M	9.9M	14.2M	10.2M	10.7M
Other Stockholder Equity	461.4M	583M	656.0M	675.8M	717.4M	422.0M
Total Current Assets	156.3M	261.6M	346.5M	230.4M	117.0M	156.5M
Accumulated Other Comprehensive Income	(1.6M)	(2.6M)	500K	(6.8M)	(3.5K)	(3.6K)
Intangible Assets	7.4M	14.6M	12.6M	27.2M	20.3M	21.3M
Other Liab	5.2M	2.1M	1.9M	2.0M	2.3M	2.7M
Net Tangible Assets	1.9M	26.2M	85.7M	96.1M	110.5M	58.3M
Property Plant And Equipment Net	33.9M	32.4M	34.1M	33.0M	23.5M	17.1M
Non Current Assets Total	70.2M	67.3M	50.0M	63.9M	50.5M	45.3M
Non Currrent Assets Other	17.7M	2.7M	3.4M	3.7M	6.7M	7.6M
Net Receivables	14.4M	19.3M	23.8M	28.3M	15.4M	13.6M
Capital Surpluse	397.4M	461.9M	583M	656.0M	754.4M	386.6M
Property Plant And Equipment Gross	33.9M	32.4M	15.1M	33.0M	32.4M	34.0M
Short Term Debt	9.0M	6.4M	7.4M	12.6M	9.5M	8.0M
Current Deferred Revenue	1.3M	1.1M	2.6M	728K	843K	800.9K

Pair Trading with Fortress Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fortress Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fortress Biotech will appreciate offsetting losses from the drop in the long position's value.

Moving against Fortress Stock

0.34

RNXT

RenovoRx

Pair Corr

The ability to find closely correlated positions to Fortress Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Fortress Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Fortress Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Fortress Biotech to buy it.

The correlation of Fortress Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Fortress Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Fortress Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Fortress Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Fortress Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fortress Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fortress Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fortress Biotech Stock:

How To Invest In Fortress

Details

Is Fortress Stock a good investment?

Details

What is Fortress Biotech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fortress Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Fortress Stock, please use our How to Invest in Fortress Biotech guide.

You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fortress Biotech. If investors know Fortress will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fortress Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(27.73)

Revenue Per Share

6.15

Quarterly Revenue Growth

(0.14)

Return On Assets

(0.36)

Return On Equity

(17.40)

The market value of Fortress Biotech is measured differently than its book value, which is the value of Fortress that is recorded on the company's balance sheet. Investors also form their own opinion of Fortress Biotech's value that differs from its market value or its book value, called intrinsic value, which is Fortress Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fortress Biotech's market value can be influenced by many factors that don't directly affect Fortress Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Fortress Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fortress Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fortress Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Fortress Total Liab vs Net Invested Capital Analysis

Total Liab vs Net Invested Capital

Total Liab vs Net Invested Capital Correlation Analysis

Correlation Coefficient

Total Liab

Net Invested Capital

Fortress Biotech fundamental ratios Correlations

Fortress Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Fortress Biotech fundamental ratios Accounts

Pair Trading with Fortress Biotech

Moving against Fortress Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Short Long Term Debt Total
Cash And Short Term Investments	+ 0.99	Cash
Short Long Term Debt Total	+ 0.99	Long Term Debt
Non Current Liabilities Total	+ 0.99	Long Term Debt
Total Current Assets	+ 0.99	Cash And Short Term Investments
Total Current Assets	+ 0.98	Total Assets

Other Stockholder Equity	- 0.96	Retained Earnings Total Equity
Retained Earnings	- 0.96	Property Plant Equipment
Other Stockholder Equity	- 0.94	Retained Earnings
Retained Earnings Total Equity	- 0.93	Total Liab
Non Current Liabilities Total	- 0.92	Retained Earnings Total Equity
Retained Earnings Total Equity	- 0.92	Short Long Term Debt Total